Following Prior Denial Decision, UnitedHealthcare Agrees to Cover Spinal Muscular Atrophy Gene Therapy
stevepb / Pixabay

Following Prior Denial Decision, UnitedHealthcare Agrees to Cover Spinal Muscular Atrophy Gene Therapy

According to a story from The Washington Post, two families affected by the rare disease spinal muscular atrophy have cause for celebration after UnitedHealthcare agreed to cover their treatment with…

Continue Reading Following Prior Denial Decision, UnitedHealthcare Agrees to Cover Spinal Muscular Atrophy Gene Therapy

FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug

According to a story from BioPortfolio, the biopharmaceutical company Genkyotex has recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application.…

Continue Reading FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug
Possible Treatment for Homozygous Familial Hypercholesterolemia Earns Orphan Drug Designation
katicaj / Pixabay

Possible Treatment for Homozygous Familial Hypercholesterolemia Earns Orphan Drug Designation

According to a story from bloomberg.com, the drug development company Arrowhead Pharmaceuticals, Inc. recently announced that its experimental product candidate AR0-ANG3 has earned Orphan Drug designation from the US Food…

Continue Reading Possible Treatment for Homozygous Familial Hypercholesterolemia Earns Orphan Drug Designation
Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away
kalhh / Pixabay

Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away

According to a story from PMLive, the US Food and Drug Administration (FDA) has recently begun the priority review process for a new potential therapy from pharmaceutical behemoth Novartis. This…

Continue Reading Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away
Phase 3 Trial of Experimental Progressive Familial Intrahepatic Cholestasis Drug for Pediatric Patients Begins
DarkoStojanovic / Pixabay

Phase 3 Trial of Experimental Progressive Familial Intrahepatic Cholestasis Drug for Pediatric Patients Begins

According to a story from drugs.com, the biopharmaceutical company Mirum Pharmaceuticals recently announced that they have begun dosing the first patient in a phase 3 clinical trial. This clinical trial…

Continue Reading Phase 3 Trial of Experimental Progressive Familial Intrahepatic Cholestasis Drug for Pediatric Patients Begins
Recent Study Finds Better Than Expected Safety Data for TNF Inhibitors in Ankylosing Spondylitis
skeeze / Pixabay

Recent Study Finds Better Than Expected Safety Data for TNF Inhibitors in Ankylosing Spondylitis

According to a story from Ankylosing Spondylitis News, a recent study has found that the class of drugs known as tumor necrosis factor (TNF) inhibitors may actually be safer for…

Continue Reading Recent Study Finds Better Than Expected Safety Data for TNF Inhibitors in Ankylosing Spondylitis
Study Identifies Broader Range of Clinical Presentation for Mitochondrial Disease
geralt / Pixabay

Study Identifies Broader Range of Clinical Presentation for Mitochondrial Disease

According to a story from Wellcome Center Mitochondrial Research, a multi-center collaborative study that involved researchers from different sites around the UK has resulted in an improved understanding of the…

Continue Reading Study Identifies Broader Range of Clinical Presentation for Mitochondrial Disease
Potential Treatment for Cystic Fibrosis Lung Infections Earns Orphan Drug Designation
geralt / Pixabay

Potential Treatment for Cystic Fibrosis Lung Infections Earns Orphan Drug Designation

According to a story from prnewswire.com, the biopharmaceutical company Aridis Pharmaceuticals, Inc. has recently announced that the US Food and Drug Administration (FDA) has awarded Orphan Drug designation to the…

Continue Reading Potential Treatment for Cystic Fibrosis Lung Infections Earns Orphan Drug Designation
Company Starts up Late Stage Trial Testing Experimental WHIM Syndrome Treatment
mwooten / Pixabay

Company Starts up Late Stage Trial Testing Experimental WHIM Syndrome Treatment

According to a story from BioPortfolio, the biopharmaceutical company X4 Pharmaceuticals, Inc. has recently initiated a phase 3 clinical trial that is testing its current lead product candidate mavorixafor. This…

Continue Reading Company Starts up Late Stage Trial Testing Experimental WHIM Syndrome Treatment